UBS Group
OMGA

UBS Group’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

UBS Group’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-163,904
Closed -$122K – 10985
2024
Q4 		$122K Buy
163,904
+160,912
+5,378% +$160K ﹤0.01% 6751
2024
Q3 		$3.65K Buy
2,992
+1,545
+107% +$2.46K ﹤0.01% 8240
2024
Q2 		$3K Sell
1,447
-26,263
-95% -$61.9K ﹤0.01% 8269
2024
Q1 		$101K Buy
27,710
+99
+0.4% +$380 ﹤0.01% 6220
2023
Q4 		$83.1K Buy
27,611
+14,490
+110% +$29.4K ﹤0.01% 6283
2023
Q3 		$28.2K Sell
13,121
-1,919
-13% -$7.67K ﹤0.01% 6617
2023
Q2 		$84.2K Buy
15,040
+10,986
+271% +$85.9K ﹤0.01% 6146
2023
Q1 		$24.4K Buy
4,054
+2,410
+147% +$16.8K ﹤0.01% 6936
2022
Q4 		$9.39K Sell
1,644
-1,960
-54% -$11K ﹤0.01% 8656
2022
Q3 		$20K Buy
+3,604
New +$18.3K ﹤0.01% 7420
2022
Q2 		– Sell
-297
Closed -$2K – 11103
2022
Q1 		$2K Sell
297
-1,455
-83% -$14.9K ﹤0.01% 9695
2021
Q4 		$20K Buy
1,752
+768
+78% +$14.6K ﹤0.01% 7857
2021
Q3 		$19K Buy
+984
New +$18.9K ﹤0.01% 7229

Other funds holding OMGA

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $6.82B AUM 17.15% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's OMGA Position: Q1 2025 in Review

UBS Group sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2025, closing a stake of 163,904 shares — an estimated $122K sold.

UBS Group first reported a position in OMGA in Q3 2021 and held it in 13 quarters. The position peaked at $122K in Q4 2024. 4 funds tracked by Wall St. Rank hold OMGA as of Q1 2025.

  • UBS Group reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 163,904 Omega Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $122K.
  • UBS Group first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 13 quarters.
  • UBS Group's Omega Therapeutics, Inc. Common Stock position peaked at $122K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.